Cohance Lifesciences shares fell around 7% after the company reported an 84% year-on-year drop in March-quarter net profit. Jefferies cut its target and downgraded the stock to Underperform, pointing to management instability and weak visibility into performance. Goldman Sachs kept a Buy rating, citing longer-term opportunities despite a rough near-term outlook.
Cohance Lifesciences shares surged 20% on Monday after appointing former Cipla CEO Umang Vohra as Executive Chairman and Group CEO. The company expects his leadership to push transformation, expand operations, and deepen global partnerships as it moves into a new growth phase. Investors reacted sharply to the change at the top.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
